重组载脂蛋白A-I_(Milano)在心血管保护及冠心病治疗中的研究进展
The study progression of recombinant apolipoprotein A-Imilano in cardiovascular protection and therapy of coronary heart disease (no abstract)
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
2005年第7期673-675,共3页
Chinese Journal of Cardiology
参考文献24
-
1Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med, 2004, 164, 1427-1436.
-
2Newton RS, Krause BR. HDL therapy for the acute treatment of atherosclerosis. Atheroscler Suppl, 2002, 3: 31-38.
-
3Price MJ, Shah PK. New strategies in managing and preventing atherosclerosis: focus on HDL. Rev Cardiovasc Med, 2002, 3: 129-137.
-
4Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA, 2003, 290:2292-2300.
-
5Franceschini G, Sirtori CR, Capurso A 2nd, et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest, 1980, 66: 892-900.
-
6Weisgraber KH, Rall SC Jr, Bersot TP, et al. Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. J Biol Chem, 1983, 258: 2508-2513.
-
7Gualandri V, Franceschini G, Sirtori CR, et al. AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet, 1985, 37:1083-1097.
-
8Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant: the Limone sul Garda study. Circulation, 2001, 103, 1949-1954.
-
9Franceschini G, Vecchio G, Gianfranceschi G, et al. Apolipoprotein AIMilano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant. J Biol Chem, 1985, 260: 16321-16325.
-
10Roma P, Gregg RE, Meng MS, et al. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia. J Clin Invest, 1993, 91:1445-1452.
-
1王炳银,刘峰.他汀类药物对心房颤动有预防作用吗[J].中华心律失常学杂志,2011,15(2):151-153. 被引量：3
-
2张莹,王安才.他汀类药物心血管保护作用的研究进展[J].疑难病杂志,2011,10(10):799-801. 被引量：8
-
3庞良芳.他汀类药物（statins）通过抑制内源性胆固醇合成限速酶还原酶[J].中国医药指南,2013,11(25):64-65. 被引量：3
-
4梁茂本.他汀类药物作用特点及用药须知[J].中国基层医药,2002,9(12):1127-1127. 被引量：1
-
5答疑解惑Q＆A[J].药品评价,2010(19):38-38.
-
6高俊,刘德培,梁植权.载脂蛋白apoA-Ⅰ抗动脉粥样硬化的相关研究[J].北京大学学报（医学版）,2001,33(4):320-322. 被引量：2
-
7赵水平.降脂药物临床疗效评价(一)[J].中国社区医师,2006,22(4):20-21. 被引量：1
-
8Grundy SM,齐爱东.治疗高胆固醇血症的HMG-CoA还原酶抑制剂[J].国外医药（合成药．生化药．制剂分册）,1989,10(4):194-200.
-
9袁志忠,梅长林,宋维.他汀类降脂药与肾脏病[J].全科医学临床与教育,2004,2(1):44-48. 被引量：2
-
10陈章强,洪浪,王洪.辛伐他汀致横纹肌溶解症一例[J].中华全科医师杂志,2008,7(8):569-570. 被引量：1
